Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLC178 in advanced malignancy
NCT02925000Phase 2Completed
- Sponsor
- Taiwan Liposome Company
- Start
- Jun 2017
- Primary completion
- Oct 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine liposome in advanced cancer, solid tumor, lymphoma and 2 more, sponsored by Taiwan Liposome Company. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Jun 2017; status: completed.
02
Drugs
vinorelbine liposome
03
Conditions
advanced cancersolid tumorlymphomaperipheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02925000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02925000.